ВЛИЯНИЕ МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИХ ИЗМЕНЕНИЙ НА ПРОГНОЗ ПРИ ОСТРОМ МИЕЛОИДНОМ ЛЕЙКОЗЕ У ДЕТЕЙ
Целью данного исследования являлся анализ прогностического значения молекулярно- генетических изменений при остром миелоидном лейкозе (ОМЛ) у детей, получавших лечение в Республике Беларусь по оригинальным протоколам ОМЛ-ММ-2000 и ОМЛ-ММ-2006. Наличие inv(16) и t(8; 21) при ОМЛ ассоциировано с благоприятным исходом. Показатели выживаемости пациентов с t(1; 11) сравнимы с таковыми в группе CBF, что также позволяет отнести данную аномалию к прогностически благоприятной. Риск развития рецидива у пациентов с t(10; 11) выше, чем у остальной когорты 11q23. Прогностическое влияние на исход болезни у лиц с нормальным кариотипом оказывает наличие либо отсутствие дополнительных генетических событий.
1. Pediatric AML: From Biology to Clinical Management / J. D. de Rooij [et al.] // J. Clin. Med. – 2015. – Vol. 4, N 1. – P. 127–149.
2. Rubnitz, J. E. Childhood Acute Myeloid Leukaemia / J. E. Rubnitz, H. Inaba // Br. J. of Haematol. – 2012. – Vol. 159, N 3. – P. 259–276.
3. Гук, Л. Г. Анализ мутаций в генах FLT3, KIT, MLL, NPM1 у детей с острым миелоидным лейкозом: автореф. дис. ... канд. мед. наук: 14.01.21 / Фед. науч.-клин. центр детск. гематол., онколог. и иммунол. – М., 2010. – 28 с.
4. Gilliland, D. G. Molecular genetics of human leukemias: new insights into therapy / D. J. Gilliland // Semin. Hematol. – 2002. – Vol. 39, N 4. – P. 6–11.
5. Takahashi, S. Сurrent findings for recurring mutations in acute myeloid leukemia / S. Takahashi // J. of Hematol. and Oncol. – 2011. – Vol. 4, N 36. – P. 1–11.
6. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Med. Res. Council Treatment Trials AML 10 and 12 / C. J. Harrison [et al.] // J. Clin. Oncol. – 2010. – Vol. 28. – P. 2674–2681.
7. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98 / C. von Neuhoff [et al.] // J. Clin. Oncol. – 2010. – Vol. 28. – P. 2682–2689.
8. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia / B. V. Вalgobind [et al.] // Haematologica. – 2011. – Vol. 96. – P. 1478–1487.
9. Faulk, K. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia / K. Faulk, L. Gore, T. Сooper // Pediatric Drugs. – 2014. – Vol. 16, N 3. – P. 213–227.
10. Rubnitz, J. E. How I treat pediatric acute myeloid leukemia / J. E. Rubnitz // Blood. – 2012. – Vol. 119, N 25. – P. 5980–5988.
11. Characterization of CEBPA mutations and promoterhypermethylation in pediatric acute myeloid leukemia / I. H. Hollink [et al.] // Haematologica. – 2011. – Vol. 96. – P. 384–392.
12. Marcucci, G. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications / G. Marcucci, T. Haferlach, H. Döhner // J. Clin. Oncol. – 2011. – Vol. 29, N 5. – P. 475–486.
13. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group / P. A. Ho [et al.] // Blood. – 2009. – Vol. 113, N 26. – P. 6558–6566.
14. Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia / D. G. Valerio [et al.] // Haematologica. – 2014. – Vol. 99, N 8. – P. 130– 132.
15. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia / B. Balgobind [et al.] // Haematologica. – 2011. – Vol. 96, N 10. – P. 1478–1487.
16. Pui, C.-H. Biology, risk stratification and therapy of pediatric acute leukemias: an update / C.-H. Pui, W. Carroll, S. Meshinchi // J. Clin. Oncol. – 2011. – Vol. 29, N 5. – P. 551–565.
17. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel / U. Creutzig [et al.] // Blood. – 2012. – Vol. 120, N 16. – P. 3187–3205.
18. Rassi, F. Update on optimal management of acute myeloid leukemia / F. Rassi, M. Arellano // Clin. Med. Insights: Oncology. – 2013. – Vol. 7. – P. 181–197.
19. Paschka, P. Сore-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? / P. Paschka, K. Dohner // Hematology. – 2013. – Vol. 2013, N 1. – P. 209–219.
20. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Ital. retrospective study / R. Сairoli [et al.] // Blood. – 2006. – Vol. 107, N 9. – P. 3463–3468.
21. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) / N. Boissel [et al.] // Leukemia. – 2006. – Vol. 20, N 6. – P. 965–970.
22. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML / J. A. Pollard [et al.] // Blood. – 2010. – Vol. 115, N 12. – P. 2372–2379.
23. Characterization of CEBPA mutations and promoterhypermethylation in pediatric acute myeloid leukemia / I. H. Hollink [et al.] // Haematologica. – 2011. – Vol. 96, N 3. – P. 384–392.
24. Marcucci, G. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications / G. Marcucci, T. Haferlach, H. Döhner // J. Clin. Oncol. – 2011. – Vol. 29, N 5. – P. 475–486.
25. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group / P. A. Ho [et al.] // Blood. – 2009. – Vol. 113, N 26. – P. 6558–6566.
26. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia / Y. Shen [et al.] // Blood. – 2011. – Vol. 118, N 20. – P. 5593–5603.
27. Сooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3 / D.-C. Liang [et al.] // Blood. – 2013. – Vol. 121, N 15. – P. 2988–2995.
28. Creutzig, U. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel / U. Creutzig, M. M. van den Heuvel-Eibrink, B. Gibson // Blood. – 2012. – Vol. 120, N 16. – P. 3187–3205.
29. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia / J. van Dongen [et al.] // Leukemia. – 1999. – Vol. 13, N 12. – P. 1901–1928.
30. Kaplan, E. Nonparametric Estimation from Incomplete Observations / E. Kaplan, P. Meier // J. of the Am. Stat. Association. – 1958. – Vol. 53, N 282. – P. 457–481.
31. Gooley, T. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators / T. Gooley, W. Leisenring, J. Crowley // Statistics in Medicine. – 1999. – Vol. 18, N 6. – P. 695–706.
32. Gray, R. A class of K-sample tests for comparing the cumulative incidence of a competing risk / R. Gray // The Annals of Statistics. – 1988. – Vol. 16, N 3. – P. 1140–1154.
33. Clinical and genetic characteristics of acute myeloid leukemia with t(8; 21) in children and results of therapy according to protocol AML-MM-2000 / I. Kalinina [et al.] // Onkogematologiya. – 2011. – Vol. 6, N 1. – P. 11–18.